Wegovy active ingredient and how semaglutide works

The biggest myth: Wegovy just suppresses your appetite

Most people arrive at this topic expecting a straightforward story: Wegovy tells your brain you're full, you eat less, you lose weight. That is part of it. But treating it as a pure appetite suppressant misses why the medicine behaves the way it does, and why the experience varies so much from person to person.

Semaglutide is a GLP-1 receptor agonist. GLP-1, glucagon-like peptide-1, is released from your gut after a meal. It signals to the pancreas, slows gastric emptying, and travels to the hypothalamus to reduce hunger. Semaglutide is a synthetic analogue of that hormone, engineered to stay active in the body for roughly seven days rather than the few minutes natural GLP-1 manages. That extended half-life is what makes a once-weekly injection viable.

So semaglutide does reduce appetite, but it does so by sustaining a hormonal signal your body already uses, not by chemically overriding your hunger. It also slows the rate at which food leaves the stomach, which extends the feeling of fullness after smaller meals. And it acts on areas of the brain involved in reward and motivation around food, which is one reason some people report that previously appealing foods feel neutral rather than tempting. If you're curious how the pharmacological mechanism of Wegovy unfolds at the receptor level, that page goes deeper on the biology.

The practical upshot: semaglutide's effect is broad. Appetite reduction is visible and often dramatic. But the gastric-slowing effect is also real, and it is the main driver of early nausea, particularly after dose increases.

What the active ingredient does at each dose stage

Wegovy is not a medicine you take at full strength from day one. The standard titration runs from 0.25 mg, stepping through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, with roughly four weeks at each level. The lower doses are not therapeutic targets in themselves, they exist to let the body adapt gradually, primarily to avoid the nausea and vomiting that can accompany the gastric-slowing effect at higher concentrations.

As the dose increases, the receptor activation intensifies and the effects on appetite and gastric motility become stronger. For most people, the sharpest changes in how food feels (portion sizes, interest in eating, tolerance for fatty or rich meals) become clearest in the upper dose range. The MHRA approved a higher 7.2 mg maintenance dose in early 2026, with a dedicated single-dose pen approved on 14 April 2026 for adults with a BMI of 30 or above; trial data at that dose reported an average weight loss of around 20.7% over 72 weeks, which narrows the gap with tirzepatide's results. You can read more about how effective the 2.5 mg starting stage is, or look at the broader evidence on Wegovy's effectiveness for context on the full range.

The prescriber sets the titration schedule and decides when, or whether, to move to the next dose. That is not an administrative decision, it reflects how your body is tolerating the medicine and what results you're seeing.

What semaglutide is not doing (and why that matters)

If you've landed here wondering whether Wegovy is the same as Ozempic, the active ingredient is identical: both contain semaglutide. The difference is the licence. Ozempic is approved for type 2 diabetes management; Wegovy is approved for weight management. They are not interchangeable for weight-loss purposes under UK prescribing rules, and prescribers cannot legally prescribe Ozempic for weight loss. The semaglutide overview covers that distinction clearly if it's a question you've been carrying.

Semaglutide is also not a fat-burning compound. It does not accelerate metabolism in any meaningful direct sense, nor does it target fat cells specifically. The weight loss it produces is driven almost entirely by reduced caloric intake, you eat less because appetite falls and meals feel satisfying sooner. If you want to understand precisely how semaglutide acts on the body's receptors and signalling pathways, that page walks through the mechanism in full. The lifestyle components of treatment (a reduced-calorie diet and increased physical activity) are not optional extras. They are built into the licence and the evidence base. The STEP 1 trial, which underpins NICE's appraisal of Wegovy, was conducted alongside structured lifestyle support, and the results reflect that combination.

It's worth being honest: a lot of people come to Wegovy feeling frustrated, by waiting lists, by previous attempts that didn't stick, by conflicting information online. That is entirely understandable. Knowing what the active ingredient actually does, rather than what the hype suggests, tends to produce better outcomes because expectations are grounded.

Eligibility, safety monitoring and next steps

Wegovy is a prescription-only medicine. In the UK, the licensed eligibility criteria for private prescribing are a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. The NHS route follows NICE TA875 criteria, which require a specialist weight management service and carry significant waiting times in most areas. Some patients also ask about bio active semaglutide formulations and how they compare to the standard licensed product. A closer look at weight-loss treatment options sets out how the routes compare.

Because semaglutide is a Black Triangle medicine, the MHRA actively monitors its safety profile in real-world use. Common side effects centre on the gastrointestinal system: nausea, loose stools, constipation and reflux are the ones most frequently reported, especially at the start or after a step-up. Severe, persistent abdominal pain that radiates to the back warrants prompt medical attention, acute pancreatitis is a known but infrequent risk with GLP-1 medicines. Patients can report any suspected side effect directly through the MHRA's Yellow Card scheme.

If you'd like to discuss whether Wegovy is clinically suitable for you, our prescribers at nume review consultations the same day, with no algorithm making the call. Start your free consultation and a GPhC-registered prescriber will assess your individual picture.